Voya Investment Management LLC Invests $978,000 in Abivax SA Sponsored ADR $ABVX

Voya Investment Management LLC purchased a new stake in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 11,515 shares of the company’s stock, valued at approximately $978,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bank of America Corp DE increased its position in Abivax by 56.1% during the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after purchasing an additional 1,990 shares during the period. HighVista Strategies LLC increased its position in shares of Abivax by 4.3% during the second quarter. HighVista Strategies LLC now owns 51,156 shares of the company’s stock valued at $391,000 after buying an additional 2,092 shares during the period. Cubist Systematic Strategies LLC raised its stake in Abivax by 34.3% in the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock worth $63,000 after buying an additional 2,595 shares in the last quarter. Kennedy Capital Management LLC lifted its holdings in Abivax by 7.1% in the second quarter. Kennedy Capital Management LLC now owns 241,188 shares of the company’s stock worth $1,845,000 after buying an additional 15,997 shares during the period. Finally, XTX Topco Ltd bought a new stake in Abivax during the 2nd quarter valued at approximately $139,000. Hedge funds and other institutional investors own 47.91% of the company’s stock.

Abivax Stock Performance

ABVX stock opened at $138.34 on Wednesday. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.86 and a quick ratio of 7.86. Abivax SA Sponsored ADR has a 1-year low of $4.77 and a 1-year high of $148.83. The business has a 50-day moving average price of $115.46 and a 200 day moving average price of $78.94. The company has a market capitalization of $10.78 billion, a P/E ratio of -33.10 and a beta of 0.48.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings results on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The firm had revenue of ($4.92) million for the quarter. As a group, equities research analysts forecast that Abivax SA Sponsored ADR will post -2.83 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ABVX. Weiss Ratings reissued a “sell (d-)” rating on shares of Abivax in a research report on Wednesday, October 8th. Truist Financial set a $140.00 price objective on Abivax in a research report on Monday, November 24th. Citizens Jmp upped their target price on shares of Abivax from $114.00 to $131.00 and gave the stock a “market outperform” rating in a research report on Tuesday, December 16th. Citigroup reissued an “outperform” rating on shares of Abivax in a research report on Tuesday, December 16th. Finally, Barclays started coverage on shares of Abivax in a report on Monday, October 13th. They issued an “overweight” rating and a $142.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $128.73.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.